Pillstats
Rx only · Capsule, Delayed Release Pellets · Oral

Pancrelipase

Brands: Creon · Pancrelipase Amylase + Pancrelipase Lipase + Pancrelipase Protease

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US8 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCA09AA01
RxCUI (US)743
US makers1 labelers
Packages22
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 8 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$1.97$3.94$5.90$7.87Dec 2025May 2026Jul 2026
$6.838
Latest avg · Jul 22, 2026
+3%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

30K59K89K118K2025 Q12025 Q22025 Q32025 Q42026 Q1
92K
Rx · 2026 Q1
22.8M
Units dispensed
-11%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
AbbVie Inc.unknown22SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Mar 15, 2021
    RECALLRecall (Class II): Creon (pancrelipase) Delayed-Release Capsules Dose By Lipase Units Lipase 36,000 USP Units Rx only NDC 0032-3016-13 100…

    CGMP Deviations: Intermittent exposure to temperature excursion during storage. — Recalling firm: Cardinal Health Inc. — FL, GA, SC

  • Sep 15, 2014
    RECALLRecall (Class II): CREON (pancrelipase) Delayed-Release Capsules, Lipase 24,000 USP Units, 250 Capsule Bottles, Rx Only. Marketed by: AbbV…

    Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000. — Recalling firm: AbbVie Inc — US: Nationwide